Investors Face New Wave of Class-Action Suits
Shareholders are being encouraged to join a fresh round of securities fraud lawsuits targeting major public companies. Law firms have recently filed suits against Bath & Body Works, opened an investigation into Nidec Corporation, and sued uniQure N.V. over alleged material misstatements and investor losses.
The legal actions against Bath & Body Works stem from allegations that the company made misleading statements about its growth strategy. The lawsuit claims the company's expansion into adjacent product categories like men's grooming, hair, and laundry products was not actually growing its customer base and that this was not properly disclosed to investors. Following announcements on August 28, 2025, and November 20, 2025, that revealed declining earnings, reduced guidance, and the failure of their strategy to attract new customers, the company's stock price dropped significantly. The first drop was 6.9% and the second was a more substantial 24.8%. The class period for investors to join the suit covers purchases made between June 4, 2024, and November 19, 2025. The investigation into Japanese motor manufacturer Nidec Corporation centers on suspected improper accounting practices. The probe, initiated in September 2025, uncovered several issues, including the misrepresentation of the country of origin for products to avoid U.S. tariffs and the potential manipulation of the timing of impairment losses. Nidec's disclosures led to a series of stock price drops, with a 16.5% fall on September 4, 2025, and another 25.4% decline on October 23, 2025, after the company withdrew its forecast and suspended its dividend. The Tokyo Stock Exchange has since placed Nidec on a "special alert," citing the need for improvement in its internal management system. The lawsuit against biotechnology firm uniQure N.V. alleges that the company misled investors about the regulatory approval prospects of its Huntington's disease gene therapy, AMT-130. The suit claims uniQure failed to disclose that the FDA had not fully approved the design of its pivotal study. When uniQure revealed on November 3, 2025, that the FDA did not agree that the existing study data was sufficient for a Biologics License Application submission, its stock plummeted by over 49%. This erased a nearly 250% gain the stock had seen earlier in the year based on positive, yet allegedly misleading, statements about the drug's progress. These lawsuits are part of a broader trend in securities litigation. In 2025, there were 207 new securities class-action lawsuits filed. While the number of filings saw a slight decrease from the previous year, the potential investor losses in these cases reached historical highs. The median settlement for securities class-action lawsuits in 2025 was $17.3 million, the highest it has been since 1997. Cases specifically involving the Securities Act of 1933, like the one against uniQure, saw a median settlement of $32.5 million, a record high.
